A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE-RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF EVO756 IN ADULTS WITH MODERATE TO SEVERE CHRONIC SPONTANEOUS URTICARIA

Registry ID

EVO756-CSU001

Source registry

HEALTH_CANADA

Status

Closed

Study type

INTERVENTIONAL

Sponsor

EVOMMUNE INC

Start date

2025-05-05

Completion date

2026-06-05

Last update

2025-04-02

Conditions

• URTICARIA

Related clinical trials

• A 52-WEEK MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, BASKET STUDY WITH AN OPEN-LABEL EXTENSION TO INVESTIGATE THE EFFICACY, SAFETY, AND TOLERABILITY OF REMIBRUTINIB (LOU064) IN CHRONIC INDUCIBLE URTICARIA (CINDU) IN ADULTS INADEQUATELY CONTROLLED BY H1-ANTIHISTAMINES

View on source registry